Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

Official Title

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

Details

Keywords

Multiple Myeloma, Plasma Cell Neoplasms, Daratumumab, Pomalidomide, Talquetamab, Teclistamab

Eligibility

Locations

  • UCSF
    San Francisco California 94143 United States
  • City of Hope National Medical Center
    Duarte California 91010 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT04108195
Phase
Phase 1 Multiple Myeloma Research Study
Study Type
Interventional
Participants
About 290 people participating
Last Updated